| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Hemoglobin subunit gamma-1;Gamma-1-globin;Hb F Agamma;Hemoglobin gamma-1 chain;Hemoglobin gamma-A chain;HBG1;PRO2979; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human FPGS |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Boster Bio Anti-FPGS Rabbit Monoclonal Antibody catalog # M02836. Tested in WB application. This antibody reacts with Human, Mouse, Rat.
Protein: T-cell surface glycoprotein CD3 zeta chain | Gene: Hemoglobin subunit gamma-1 | Target: FPGS | Function: Gamma chains make up the fetal hemoglobin F, in combination with alpha chains. | Research areas: Acetylation,Chromatin Modifying Enzymes,Epigenetics and Nuclear Signaling,Pol II Transcription,Polymerase Associated Factors,Transcription
Host: Rabbit | Clonality/Clone: Monoclonal / Clone: 29F90 | Isotype: IgG | Reactivity: Human,Mouse,Rat | Immunogen: A synthesized peptide derived from human FPGS | Concentration: 0.5mg/ml | Purification: Affinity-chromatography
Applications: WB
Observed MW: 60 kDa | Calculated MW: 16140 MW
Cellular localization: Cytoplasm .
Tissue details: Red blood cells.
Status: Active
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
